# AN2 Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/an2-therapeutics

- Industry: Biotechnology
- Headquarters: Menlo Park, US
- Website: www.an2therapeutics.com
- Total disclosed funding: $92M
- Latest round: Series B (Jan 7, 2022)
- Investors on record: 10

## About

Based in California, AN2 Therapeutics, Inc. is focused on developing innovative therapies for serious infectious diseases using a specialized boron-based chemistry platform.AN2 Therapeutics, Inc. was founded in 2017 and is headquartered in Menlo Park, California, US. The company specializes in innovative therapeutics for chronic infectious diseases. Eric Easom and Joe Zakrzewski are the founders, with Eric Easom currently serving as CEO. The company has engaged in 5 deals, with the most recent funding round being a PIPE in March 2022, where they raised USD 70.00 mn. The investment was directed toward advancing their development candidate, epetraborole.AN2 Therapeutics specializes in developing novel therapies targeting rare, chronic, and serious infectious diseases through its advanced boron-based chemistry platform. The company's product pipeline includes innovative compounds with the potential for best-in-class therapeutics for infectious diseases and oncology, focusing on first-in-class treatments to meet critical unmet medical needs globally.AN2 Therapeutics generates revenue through partnerships and collaborations with pharmaceutical companies and healthcare organizations. Their revenue model includes milestone payments, royalties, or licensing agreements associated with the development and commercialization of their therapeutic offerings. The company's EBITDA for the most recent year, 2023, is reported at USD -69.64 mn.AN2 Therapeutics plans to utilize the funds raised in March 2022 to support the advancement of epetraborole, a once-daily, orally-administered investigational treatment for chronic non-tuberculous mycobacterial lung disease (NTM). The company aims to further develop its pipeline and expand its presence in the therapeutic landscape for infectious diseases and oncology, although specific new product launches and market expansions have not been detailed.

## Funding rounds

- Series B, Jan 7, 2022, $80M — Hatteras Venture Partners, BVF Partners, RA Capital Management, Monashee Investment Management, Surveyor Capital, Avidity Partners
- Series A, Sep 21, 2019, $12M — Mountain Group Partners, Brii Biosciences Limited, BioRock Ventures, Adjuvant Capital

## Investors

- Mountain Group Partners (https://capitalatlas.ai/funds/mountain-group-partners) — Series A
- Brii Biosciences Limited — Series A
- BioRock Ventures (https://capitalatlas.ai/funds/biorock-ventures) — Series A
- Adjuvant Capital (https://capitalatlas.ai/funds/adjuvant-capital) — Series A
- Hatteras Venture Partners (https://capitalatlas.ai/funds/hatteras-venture-partners) — Series B
- BVF Partners (https://capitalatlas.ai/funds/bvf-partners) — Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B
- Monashee Investment Management — Series B
- Surveyor Capital — Series B
- Avidity Partners — Series B